We are live on ! Find out more
CTKB icon

Cytek Biosciences
CTKB

74 hedge funds and large institutions have $515M invested in Cytek Biosciences in 2022 Q1 according to their latest regulatory filings, with 29 funds opening new positions, 33 increasing their positions, 9 reducing their positions, and 7 closing their positions.

New
Increased
Maintained
Reduced
Closed

314% more first-time investments, than exits

New positions opened: 29 | Existing positions closed: 7

267% more repeat investments, than reductions

Existing positions increased: 33 | Existing positions reduced: 9

42% more funds holding

Funds holding: 52 → 74 (+22)

9.38% more ownership

Funds ownership: 26.2% → 35.59% (+9.4%)

0% more funds holding in top 10

Funds holding in top 10: 2 → 2 (0)

10% less capital invested

Capital invested by funds: $572M → $515M (-$57.2M)

Holders
74
Holders Change
+22
Holders Change %
+42.31%
% of All Funds
1.17%
Holding in Top 10
2
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.03%
New
29
Increased
33
Reduced
9
Closed
7
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Vanguard Group
Vanguard Group
Pennsylvania
+$69.4M
2
RCM
RA Capital Management
Massachusetts
+$51M
3
BlackRock
BlackRock
New York
+$50.3M
4
State Street
State Street
Massachusetts
+$14.2M
5
D.E. Shaw & Co
D.E. Shaw & Co
New York
+$9.7M

Top Sellers

Rank Fund Capital Flow
1
O
OrbiMed
New York
-$31.4M
2
Fidelity Investments
Fidelity Investments
Massachusetts
-$29M
3
Fidelity International
Fidelity International
Bermuda
-$28.1M
4
MGM
Miura Global Management
New York
-$10.3M
5
OCA
Octagon Capital Advisors
New York
-$6.53M
Name Holding Trade Value Shares
Change 		Change in
Stake
RCM
1
RA Capital Management
Massachusetts
$144M +$51M +3,774,026 +39%
HA
2
HHLR Advisors
Cayman Islands
$94.4M – – –
Vanguard Group
3
Vanguard Group
Pennsylvania
$68.5M +$69.4M +5,140,344 +424%
BlackRock
4
BlackRock
New York
$65.7M +$50.3M +3,722,881 +157%
MGM
5
Miura Global Management
New York
$24.3M -$10.3M -765,000 -25%
State Street
6
State Street
Massachusetts
$14.2M +$14.2M +1,048,629 +385%
Geode Capital Management
7
Geode Capital Management
Massachusetts
$9.93M +$7.64M +566,000 +159%
D.E. Shaw & Co
8
D.E. Shaw & Co
New York
$7.91M +$9.7M +718,217 +4,534%
Northern Trust
9
Northern Trust
Illinois
$7.63M +$7.4M +547,658 +343%
Goldman Sachs
10
Goldman Sachs
New York
$7M +$7.96M +589,229 +981%
Point72 Asset Management
11
Point72 Asset Management
Connecticut
$6.8M +$8.52M +631,000 New
Fidelity International
12
Fidelity International
Bermuda
$6.29M -$28.1M -2,083,238 -78%
Two Sigma Investments
13
Two Sigma Investments
New York
$5.65M +$7.08M +524,421 New
Fidelity Investments
14
Fidelity Investments
Massachusetts
$5.59M -$29M -2,148,371 -81%
PVI
15
Pura Vida Investments
New York
$4.58M +$37.8K +2,800 +0.7%
N
16
Nuveen
North Carolina
$3.98M +$3.8M +281,263 +408%
Charles Schwab
17
Charles Schwab
California
$3.13M +$2.49M +184,142 +174%
Bank of New York Mellon
18
Bank of New York Mellon
New York
$2.87M +$2.88M +213,476 +404%
Bank of America
19
Bank of America
North Carolina
$2.63M +$3.22M +238,217 +4,164%
CSS
20
Cubist Systematic Strategies
Connecticut
$2.54M +$3.18M +235,633 New
SCM
21
Soleus Capital Management
Connecticut
$1.94M +$2.43M +180,000 New
Janus Henderson Group
22
Janus Henderson Group
United Kingdom
$1.46M +$1.83M +135,198 New
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund
23
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund
Ontario, Canada
$1.37M +$1.71M +126,800 New
Morgan Stanley
24
Morgan Stanley
New York
$1.27M +$1.52M +112,808 +2,221%
Millennium Management
25
Millennium Management
New York
$1.27M +$1.59M +117,774 New
1
2 3 4

CTKB Hedge Fund Activity: Q1 2022 in Review

74 of the 6,340 institutional investors tracked by Wall St. Rank reported a position in Cytek Biosciences (CTKB) for Q1 2022, worth a combined $515M — down 10% from $572M a quarter earlier.

Buyers outnumbered sellers: 29 funds opened new CTKB positions and 7 closed out — a net gain of 22 holders — while 33 added to existing stakes and 9 trimmed.

The largest buyer was Vanguard Group, adding an estimated $69.4M. The largest seller was OrbiMed, exiting entirely with an estimated $31.4M sold.

  • 74 institutional investors held Cytek Biosciences (CTKB) as of Q1 2022, up from 52 in Q4 2021.
  • Funds reported $515M of Cytek Biosciences stock for Q1 2022, down 10% quarter-over-quarter.
  • 29 funds opened new Cytek Biosciences positions in Q1 2022 and 7 closed out, a net change of +22 holders.
  • The largest Cytek Biosciences buyer in Q1 2022 was Vanguard Group, an estimated $69.4M added.
  • The largest Cytek Biosciences seller in Q1 2022 was OrbiMed, an estimated $31.4M sold.

Based on aggregated 13F filings for Q1 2022.